HILE(SH:603718) Sou Hu Cai Jing·2025-08-06 11:01Company Overview - Haili Biological's closing price on August 6 was 7.58 yuan, down 1.17%, with a rolling PE ratio of 26.75 times and a total market value of 4.97 billion yuan [1] - The company ranks 54th in the medical device industry, which has an average PE ratio of 53.93 times and a median of 37.81 times [1] Shareholder Information - As of March 31, 2025, Haili Biological had 31,505 shareholders, a decrease of 1,319 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Segments - The main business segments of Shanghai Haili Biological Technology Co., Ltd. are in vitro diagnostic reagents (IVD) and oral tissue repair and regeneration materials, with key products including veterinary biological products and medical devices [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved operating revenue of 61.79 million yuan, a year-on-year decrease of 12.11%, while net profit was 10.90 million yuan, a year-on-year increase of 393.11%, with a gross profit margin of 75.96% [1]